DiaMedica Inc. Share Price Toronto S.E.
Equities
DMA
CA25253T1075
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- CAD | - |
05-09 | Transcript : DiaMedica Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024 | |
04-17 | DiaMedica Therapeutics Launches Late-Stage Trial of Potential Stroke Treatment | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 155M 114M 9B |
---|---|---|---|---|---|
Net income 2024 * | -36M -26.43M -2.09B | Net income 2025 * | -47M -34.51M -2.72B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.34
x | P/E ratio 2025 * |
-3.5
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.96% |
Latest transcript on DiaMedica Inc.
Managers | Title | Age | Since |
---|---|---|---|
Rick Pauls
CEO | Chief Executive Officer | 52 | 31/03/05 |
Scott Kellen
DFI | Director of Finance/CFO | 59 | 31/03/18 |
Ambarish Shah
CTO | Chief Tech/Sci/R&D Officer | - | 30/04/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Kuntz
BRD | Director/Board Member | 66 | 29/05/23 |
Tanya Lewis
BRD | Director/Board Member | 53 | 28/02/23 |
James Parsons
BRD | Director/Board Member | 58 | 19/10/10 |
1st Jan change | Capi. | |
---|---|---|
+7.52% | 113B | |
+11.38% | 106B | |
-12.64% | 22.22B | |
+0.44% | 22.27B | |
-4.18% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+37.41% | 12.52B | |
-23.95% | 8.34B |
- Stock Market
- Equities
- DMAC Stock
- DMA Stock